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Introduction {#jah31629-sec-0004}
============

Coronary artery spasm (CAS) is a well‐known endothelial dysfunction, and a major cause of vasospastic angina (VSA).[1](#jah31629-bib-0001){ref-type="ref"} Obstructive CAS could lead to myocardial infarction (MI), acute coronary syndrome (ACS), and even sudden cardiac death.[2](#jah31629-bib-0002){ref-type="ref"}, [3](#jah31629-bib-0003){ref-type="ref"}, [4](#jah31629-bib-0004){ref-type="ref"} Recently, the prevalence of CAS, as documented with the acetylcholine (Ach) provocation test, was reported at a rate of 33.4% to 57.6% in Western countries (consisted mostly of whites), 54.7% for South Korea, and 40% to 79% for Japan in Asian countries.[5](#jah31629-bib-0005){ref-type="ref"}, [6](#jah31629-bib-0006){ref-type="ref"}, [7](#jah31629-bib-0007){ref-type="ref"}

Calcium channel blockers (CCBs) and nitrates are primary medications in the management of VSA as they are known to be effective in reducing cardiovascular complications.[8](#jah31629-bib-0008){ref-type="ref"} Despite the availability of these treatment options, persistent angina remains a challenging problem.[5](#jah31629-bib-0005){ref-type="ref"}, [9](#jah31629-bib-0009){ref-type="ref"} In addition, chronic use of nitrates may lead to problems in tolerance, and even further raise cardiovascular risks.[10](#jah31629-bib-0010){ref-type="ref"}, [11](#jah31629-bib-0011){ref-type="ref"} Therefore, renin--angiotensin system (RAS) inhibitors such as the angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker may be effective in treating CAS patients since RAS is known to be closely associated with endothelial function, and RAS inhibitors are known to improve endothelial dysfunctions in patients with hypertension.[12](#jah31629-bib-0012){ref-type="ref"}, [13](#jah31629-bib-0013){ref-type="ref"} However, the long‐term efficacy of RAS inhibitors on CAS patients is not thoroughly assessed. Thus, we sought to evaluate the impact of RAS inhibitors on long‐term clinical outcomes of CAS patients.

Methods {#jah31629-sec-0005}
=======

The design of this registry has been introduced before.[5](#jah31629-bib-0005){ref-type="ref"} In brief, it is a single‐center, prospective, all‐comer registry designed to reflect "real world" practice since 2004. Data were collected by a trained study‐coordinator with a standardized case report form. Standardized definitions of all patient‐related variables and clinical diagnoses were used. The participants or their legal guardians were given a thorough literal and verbal explanation of the study procedures before granting a written consent to participate in the study. Institutional Review Board of Korea University Guro Hospital approved all of the consenting procedures. The authors of this article have certified that the information contained herein is true and correct as reflected in the records of the Institutional Review Board (\#KUGH10045). Korea University Guro Hospital Institutional Review Board specifically approved this entire study.

Those enrolled in this study, a total of 10 177 patients with typical or atypical chest pain, underwent coronary angiography (CAG) at the Cardiovascular Center of Korea University Guro Hospital, Seoul, South Korea between November 2004 and May 2014. Among these, 6430 patients with typical or atypical chest pain without significant coronary artery disease (defined as having a stenosis diameter of less than 70% on the quantitative coronary angiography) underwent the intracoronary Ach provocation test. Patients were excluded if they had any of the following conditions: coronary artery bypass graft, prior percutaneous coronary intervention, prior cerebrovascular disease, advanced heart failure (New York Heart Association class III or IV), or serum creatinine ≥2 mg/dL, because these conditions could be major causes for adverse cardiovascular events and could bias the results. Of total, 3349 CAS patients were enrolled for this study and divided into 2 groups based on whether they have been on RAS inhibitor therapy or not: The RAS inhibitor group (n=666) and non‐RAS inhibitor group (n=2683) (Figure [1](#jah31629-fig-0001){ref-type="fig"}).

![Flow chart. CAS, coronary artery spasm; PSM, propensity score matching; RAS, renin--angiotensin system.](JAH3-5-e003217-g001){#jah31629-fig-0001}

Study Definition {#jah31629-sec-0006}
----------------

Significant CAS was defined as greater than 70% of luminal narrowing of the artery during the Ach provocation test regardless of ischemic ECG changes or presence of chest pain. Deaths were regarded to be of cardiac cause unless a noncardiac death could be confirmed. Repeated CAG (mostly due to the recurrent angina)[5](#jah31629-bib-0005){ref-type="ref"}, [9](#jah31629-bib-0009){ref-type="ref"}, [14](#jah31629-bib-0014){ref-type="ref"} was performed in patients who complained of recurrent angina despite adequate antianginal medication for at least 6 months since the onset of first CAS. In this case, the physician assumed that CAS may be progressed or there may be newly developing atherosclerotic coronary artery disease. Major adverse cardiovascular events (MACE) were defined as the composite of total death, recurrent MI, and revascularization including percutaneous coronary intervention and coronary artery bypass graft. Hypertension was diagnosed according to the history of hypertension and treatment with medications, diet, and/or exercises.

Ach Provocation Test {#jah31629-sec-0007}
--------------------

The design of the Ach provocation test has been introduced before.[5](#jah31629-bib-0005){ref-type="ref"}, [14](#jah31629-bib-0014){ref-type="ref"}, [15](#jah31629-bib-0015){ref-type="ref"}, [16](#jah31629-bib-0016){ref-type="ref"}, [17](#jah31629-bib-0017){ref-type="ref"} An initial investigation for CAG included clinical history taking and noninvasive stress tests such as treadmill test, stress echocardiography, and radionuclide study. Then the CAG was performed to confirm the presence of significant coronary artery disease. However, CAG was immediately done without functional studies in case of typical resting ischemic chest pain to confirm VSA. Vasodilators or vasoconstrictors such as nitrates, CCBs, β‐blockers, nicorandil, molsidomine, etc, were discontinued at least 72 hours before the CAG. CAS induction was tested by intracoronary injection of Ach immediately after a diagnostic angiography by either a transradial or transfemoral approach. Ach was injected by incremental doses of 20 (A1), 50 (A2), and 100 (A3) μg/min into the left coronary artery over a 1‐minute period with 5‐minute intervals up to the maximal tolerated dose under continuous monitoring by ECG and measuring blood pressure. Provocation of the right coronary artery was not done routinely due to safety issues, as the insertion of a temporary pacemaker is needed to prevent advanced atrioventricular block during Ach infusion. The angiography was repeated after each Ach dose until a significant focal or diffuse narrowing of greater than 70% was observed. If significant focal or diffuse vasoconstriction (\>70%) of coronary arteries was induced at any dose, Ach infusion was stopped. An intracoronary injection of 0.2 mg of nitroglycerine was administered after completing the Ach provocation test, followed by a CAG 2 minutes later. End‐systolic images for each segment of the left coronary artery were chosen according to the corresponding points on the electrocardiographic trace (QRS onset or end of T wave) and analyzed using the proper quantitative coronary angiography system of the catheterization laboratory (FD‐20; Phillips, Amsterdam, the Netherlands). The coronary artery diameters were measured by quantitative coronary angiography before and after the administration of Ach at the site that showed the greatest changes following drug administration. Reference vessel diameters were measured at the proximal and distal portions of each artery. The mean reference vessel diameter was used to assess diameter narrowing by quantitative coronary angiography. Myocardial bridge was defined as the characteristic phasic systolic compression of the coronary artery with a decrease of more than 30% in diameter on the angiogram after intracoronary nitroglycerin infusion, mostly in anterior--posterior cranial or right anterior oblique cranial projections. Multivessel spasm was defined as significant CAS of more than 2 major epicardial arteries. Diffuse CAS was defined as significant CAS with the site length of more than 30 mm. Spontaneous spasm was defined as focal or diffuse narrowing of greater than 30% in baseline CAG, compared to the reference vessel diameter after a nitroglycerin administration into the intracoronary route.

Statistical Analysis {#jah31629-sec-0008}
--------------------

For continuous variables, differences between the 2 groups were evaluated by unpaired *t*‐test or Mann--Whitney rank test. Data were expressed as mean±SD. For discrete variables, differences were expressed as counts and percentages and analyzed with χ^2^ or Fisher\'s exact test between the 2 groups. To adjust for any potential confounders, propensity score matching (PSM) analysis was performed using the logistic regression model. We tested all available variables that could be of potential relevance: age, sex, cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia, current smokers, and current alcoholics), angiographic and clinical parameters (myocardial bridge, Ach dose \[20, 50, and 100 μg/min\], CAS site \[left arterial descending, left circumflex\], number of CAS vessels, CAS length, ECG change, chest pain, and atrioventricular block), and medical treatment (RAS inhibitors, CCBs, nitrate, trimetazidine, molsidomine, β‐blockers, diuretics, aspirin, clopidogrel, cilostazol, warfarin, and statins). Matching was performed with the use of a 1:1 matching protocol without a replacement (nearest neighbor matching algorithm), with caliper width equal to 0.05 of the SD of the propensity score. Various clinical outcomes were estimated with the Kaplan--Meier method, and differences between the groups were compared with the log‐rank test before and after PSM. Cox‐proportional hazard models were used to assess the hazard ratio (HR) of the RAS inhibitor group compared with the non‐RAS inhibitor group. For all analyses, a 2‐sided *P*\<0.05 was considered statistically significant. All data were processed with SPSS version 20.0 (SPSS‐PC, Inc, Chicago, IL).

Study End Points {#jah31629-sec-0009}
----------------

Primary end point was the incidence of total death, MI, de novo percutaneous coronary intervention, and MACE. Secondary end point was recurrent angina requiring repeat CAG. In this study, mean follow‐up period was 1213±582 days (after PSM: 1217±589) and we followed up on the clinical data of all enrolled patients through face‐to‐face interviews at regular outpatient clinic, medical chart reviews, and telephone contacts.

Results {#jah31629-sec-0010}
=======

Baseline Clinical and Laboratory Characteristics {#jah31629-sec-0011}
------------------------------------------------

For this study, a total of 3349 CAS patients were enrolled, and among these 19.8% of patients fell into the RAS inhibitors group (Figure [1](#jah31629-fig-0001){ref-type="fig"}). Baseline clinical and laboratory characteristics are shown in Table [1](#jah31629-tbl-0001){ref-type="table-wrap"}. In the overall population, there was a considerable imbalance between the RAS inhibitor group and non‐RAS inhibitor group in baseline clinical and angiographic characteristics such as sex, age, blood pressure, body mass index, left ventricular ejection fraction %, history of hypertension, diabetes mellitus, and dyslipidemia. After adjusting for baseline differences using PSM, the baseline clinical and laboratory characteristics of the 2 matched groups (524 pairs, n=1048 total) were balanced in all measured criteria (Table [1](#jah31629-tbl-0001){ref-type="table-wrap"}). Among these, 75.7% had a history of hypertension.

###### 

Baseline Clinical Characteristics and Laboratory Findings

  Variable, N (%)               Entire Patients   Matched Patients                                       
  ----------------------------- ----------------- ------------------ --------- ------------ ------------ ---------
  Sex (male)                    379 (56.9)        1359 (50.6)        0.004     293 (55.9)   307 (58.5)   0.382
  Age, y                        59.4±10.6         55.9±11.6          \<0.001   58.9±10.4    59.3±11.1    0.505
  Blood pressure (BP)                                                                                    
  Systolic BP                   140±21            132±19             \<0.001   140±21       136±21       0.001
  Diastolic BP                  80±13             76±12              \<0.001   81±12        78±12        \<0.001
  Body mass index               25.5±3.2          24.1±3.0           \<0.001   25.5±3.2     24.8±3.0     \<0.001
  LVEF, %                       58.1±5.4          59.2±3.3           \<0.001   58.6±5.1     59.0±3.6     0.236
  Risk factors                                                                                           
  Hypertension                  533 (80.0)        956 (35.6)         \<0.001   394 (75.1)   400 (76.3)   0.665
  Diabetes mellitus             180 (27.0)        385 (14.3)         \<0.001   125 (23.8)   120 (22.9)   0.715
  New‐onset diabetes mellitus   43 (6.4)          87 (3.2)           \<0.001   24 (4.5)     32 (6.1)     0.272
  Insulin                       29 (4.3)          36 (1.3)           \<0.001   18 (3.4)     16 (3.0)     0.727
  Medication                    112 (16.8)        242 (9.0)          \<0.001   82 (15.6)    73 (13.9)    0.434
  Dietary                       11 (1.6)          33 (1.2)           0.392     11 (2.0)     7 (1.3)      0.342
  Dyslipidemia                  321 (48.1)        768 (28.6)         \<0.001   228 (43.5)   245 (46.7)   0.291
  Smokers                       234 (35.1)        888 (33.0)         0.319     175 (33.3)   186 (35.4)   0.475
  Current smokers               155 (23.2)        640 (23.8)         0.753     115 (21.9)   129 (24.6)   0.306
  Alcohol drinkers              276 (41.4)        1021 (38.0)        0.108     211 (40.2)   218 (41.6)   0.660
  Current drinkers              246 (36.9)        943 (35.1)         0.388     191 (36.4)   199 (37.9)   0.609
  Laboratory findings                                                                                    
  Total cholesterol             175±39            180±37             0.012     177±38       178±43       0.671
  HDL cholesterol               49±12             51±13              0.023     49±12        49±12        0.540
  LDL cholesterol               110±34            113±33             0.067     112±34       111±38       0.666
  Triglyceride                  143±11            126±84             0.003     141±11       142±11       0.851
  High‐sensitivity CRP          3.1±9.2           2.7±10.7           0.588     2.7±7.5      3.3±11.9     0.506
  Fasting blood glucose         107±26            101±21             \<0.001   106±25       105±21       0.564
  Hemoglobin A1c, %             6.3±1.0           5.9±0.7            \<0.001   6.2±1.0      6.1±0.8      0.521
  Insulin                       10.8±12.0         10.0±6.7           0.430     9.7±6.0      11.5±7.6     0.101
  Hemoglobin                    13.6±1.5          13.5±1.5           0.305     13.7±1.5     13.6±1.6     0.548
  Hematocrit                    40.4±4.3          40.1±4.3           0.158     40.6±4.3     40.4±4.5     0.506
  Creatinine                    0.7±0.1           0.7±0.1            \<0.001   0.7±0.1      0.7±0.1      0.589
  Uric acid                     5.2±1.4           4.8±1.4            \<0.001   5.2±1.4      5.2±1.5      0.982

Data are presented as N (%) or mean±SD. CRP indicates C‐reactive protein; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; RAS, renin--angiotensin system.

Ach Provocation Test Results {#jah31629-sec-0012}
----------------------------

During the Ach provocation test, the incidence of CAS and angiographic and clinical characteristics was similar between the 2 groups after PSM analysis (Table [2](#jah31629-tbl-0002){ref-type="table-wrap"}). The use of RAS inhibitors did not have any impact on angiographic and clinical parameters during the Ach provocation test.

###### 

Angiographic and Clinical Characteristics During Acetylcholine Provocation Test

  Variable, N (%)                           Entire Patients   Matched Patients                                       
  ----------------------------------------- ----------------- ------------------ --------- ------------ ------------ -------
  Quantitative coronary angiography (QCA)                                                                            
  MND, mm (during Ach Test)                 0.7±0.3           0.7±0.3            0.802     0.7±0.3      0.6±0.3      0.217
  MND, % (during Ach Test)                  70.4±12.5         70.4±12.9          0.939     70.3±12.4    71.4±13.2    0.154
  RD, mm (after NTG injection)              2.3±0.5           2.3±0.7            0.985     2.3±0.5      2.3±0.5      0.070
  Ach dose                                                                                                           
  A1 (20 μg)                                35 (5.2)          150 (5.5)          0.747     27 (5.1)     37 (7.0)     0.200
  A2 (50 μg)                                249 (37.5)        944 (35.1)         0.265     191 (36.5)   187 (35.6)   0.779
  A3 (100 μg)                               380 (57.2)        1589 (59.2)        0.349     305 (58.3)   300 (57.2)   0.727
  Spasm site                                                                                                         
  Left anterior descending                  617 (92.6)        2528 (94.2)        0.127     487 (92.9)   495 (94.4)   0.309
  Left circumflex                           268 (40.2)        1011 (37.6)        0.224     204 (38.9)   194 (37.0)   0.524
  Spasm position                                                                                                     
  Proximal to distal                        256 (38.4)        1115 (41.5)        0.143     202 (38.5)   215 (41.0)   0.412
  Mid to distal                             299 (44.8)        1007 (37.5)        \<0.001   231 (44.0)   216 (41.2)   0.349
  Proximal only                             33 (4.9)          210 (7.8)          0.011     29 (5.5)     27 (5.1)     0.784
  Mid only                                  64 (9.6)          306 (11.4)         0.186     53 (10.1)    58 (11.0)    0.616
  Distal only                               14 (2.1)          45 (1.6)           0.456     9 (1.7)      8 (1.5)      0.807
  Diffuse spasm                             584 (87.6)        2298 (85.6)        0.174     458 (87.4)   463 (88.3)   0.636
  Multivessel spasm                         223 (33.4)        885 (32.9)         0.807     169 (32.2)   170 (32.4)   0.947
  ECG change                                42 (6.3)          169 (6.2)          0.994     36 (6.8)     32 (6.1)     0.616
  ST‐segment elevation                      18 (2.7)          52 (1.9)           0.217     15 (2.8)     9 (1.7)      0.215
  ST‐segment depression                     12 (1.8)          63 (2.3)           0.394     10 (1.9)     14 (2.6)     0.409
  T‐inversion                               5 (0.7)           32 (1.1)           0.329     5 (0.9)      3 (0.5)      0.478
  Atrial fibrillation                       7 (1.0)           22 (0.8)           0.565     6 (1.1)      6 (1.1)      1.000
  AV block                                  163 (24.4)        718 (26.7)         0.230     135 (25.7)   125 (23.8)   0.474
  Chest pain                                427 (64.1)        1740 (64.8)        0.721     344 (65.6)   335 (63.9)   0.561

Data are presented as N (%) or mean±SD. Ach indicates acetylcholine; AV, atrioventricular; MND, minimum narrowing diameter; NTG, nitroglycerin; RAS, renin--angiotensin system; RD, reference diameter.

Medications for CAS {#jah31629-sec-0013}
-------------------

In the overall population, there was a considerable imbalance between the RAS inhibitor group and non‐RAS inhibitor group, in medications such as calcium channel blockers, diltiazem, nitrate, trimetazidine, molsidomine, β‐blockers, diuretics, aspirin, clopidogrel, cilostazol, warfarin, and statins. However, after a matched analysis, the medical treatments were balanced between the 2 groups (Table [3](#jah31629-tbl-0003){ref-type="table-wrap"}).

###### 

Medication Treatments for Coronary Artery Spasm

  Variable, N (%)   Entire Patients   Matched Patients                                       
  ----------------- ----------------- ------------------ --------- ------------ ------------ ---------
  RAS inhibitors                                                                             
  ARBs              550 (82.5)        0 (0.0)            \<0.001   428 (81.6)   0 (0.0)      \<0.001
  ACE inhibitors    138 (20.7)        0 (0.0)            \<0.001   116 (22.1)   0 (0.0)      \<0.001
  CCBs              543 (81.5)        2290 (85.3)        0.015     439 (83.7)   435 (83.0)   0.740
  Diltiazem         511 (76.7)        2230 (83.1)        \<0.001   415 (79.1)   416 (79.3)   0.939
  Nitrate           487 (73.1)        1707 (63.6)        \<0.001   372 (70.9)   377 (71.9)   0.732
  Trimetazidine     375 (56.3)        1409 (52.5)        0.079     295 (56.2)   295 (56.2)   1.000
  Molsidomine       52 (7.8)          196 (7.3)          0.658     37 (7.0)     41 (7.8)     0.638
  β‐blockers        125 (18.7)        182 (6.7)          \<0.001   78 (14.8)    71 (13.5)    0.536
  Diuretics         187 (28.0)        114 (4.2)          \<0.001   93 (17.7)    77 (14.6)    0.180
  Aspirin           252 (37.8)        292 (10.8)         \<0.001   161 (30.7)   156 (29.7)   0.737
  Statins           411 (61.7)        964 (35.9)         \<0.001   299 (57.0)   318 (60.6)   0.233

Data are presented as N (%). ACE inhibitors indicates angiotensin‐converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; RAS, renin--angiotensin system.

Clinical Outcomes {#jah31629-sec-0014}
-----------------

Figure [2](#jah31629-fig-0002){ref-type="fig"} showed the incidence of individual and composite cumulative clinical outcomes. There was no difference between the RAS inhibitor group and non‐RAS inhibitor group during the 5‐year follow‐up. However, after a matched analysis, major clinical end points such as the incidence of recurrent angina, total death, and MACE (composed of total death, myocardial infarction, and percutaneous coronary intervention) were significantly lower in the RAS inhibitor group compared with the non‐RAS inhibitor group.

![Cumulative survival curve of the various end points before and after propensity score matching. Figure shows the cumulative incidences of mortality, myocardial infarction, de novo percutaneous coronary intervention (PCI), recurrent angina, and the composite of death, myocardial infarction, or de novo PCI (MACE). The renin--angiotensin system (RAS) inhibitor group (indicated by red) received RAS inhibitors such as angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors. The "none" group (indicated by blue) received no RAS inhibitors. HR indicates hazard ratio; MACE, major adverse cardiac events.](JAH3-5-e003217-g002){#jah31629-fig-0002}

Subgroup Analysis {#jah31629-sec-0015}
-----------------

To determine whether there is any difference in outcome among various subgroups during the 5‐year follow‐up, we calculated a propensity‐score adjusted HR for total MACE and recurrent angina. Compared with the non‐RAS inhibitor group, the RAS inhibitor group showed a significantly reduced risk for total MACE (HR: 0.406, 95% CI: 0.175--0.942) and recurrent angina (HR: 0.678, 95% CI: 0.465--0.988). Moreover, RAS inhibitor was associated with improved outcomes. Compared with the non‐RAS inhibitor group, the RAS inhibitor group was associated with a significantly lower incidence of total MACE in subgroups: elderly (≥60), female, uncontrolled blood pressure, uncontrolled hypertension, diabetes mellitus, dyslipidemia, and co‐medical treatment with CCBs (Figure [3](#jah31629-fig-0003){ref-type="fig"}). In addition, the RAS inhibitor group was associated with a significantly lower incidence of recurrent angina than the non‐RAS inhibitor group in subgroups: elderly (≥60), female, uncontrolled blood pressure BP, multivessel spasm, and co‐medical treatment with nitrates, diuretics, and nonaspirin medication (Figure [3](#jah31629-fig-0003){ref-type="fig"}).

![Comparative propensity‐score adjusted hazard ratios of total MACE and recurrent angina for subgroups. Figure shows the risk of total MACE and recurrent angina in various subgroups. The RAS inhibitor group was compared with the non‐RAS inhibitor group. Hazard ratio of the entire population was adjusted by a propensity score. Data are presented as hazard ratios and 95% CIs. CCBs indicates calcium channel blockers; MACE, major adverse cardiac events; RAS, renin--angiotensin system.](JAH3-5-e003217-g003){#jah31629-fig-0003}

Discussion {#jah31629-sec-0016}
==========

The main findings of this study are as follows: (1) Chronic RAS inhibitor therapy, as compared with non‐RAS inhibitor therapy, was associated with lower incidence of cardiovascular events in VSA patients. (2) In terms of total MACE, RAS inhibitor was effective in subgroups with relatively high‐risk profiles such as elderly (≥60), female, uncontrolled blood pressure, uncontrolled hypertension, diabetes mellitus, dyslipidemia, and co‐medical treatment with CCBs. (3) Also, in terms of recurrent angina requiring a follow‐up CAG, RAS inhibitor was effective in subgroups with the following characteristic profiles: elderly (≥60), female, uncontrolled blood pressure, multivessel spasm, and co‐medical treatment with nitrates, diuretics, and nonaspirin user.

As aforementioned, endothelial dysfunction is the well‐known main mechanism of CAS.[1](#jah31629-bib-0001){ref-type="ref"} The other mechanism of CAS is hyperreactivity of vascular smooth muscle cells.[18](#jah31629-bib-0018){ref-type="ref"} The action of angiotensin II on smooth muscle cells produces contraction and also proliferation.[13](#jah31629-bib-0013){ref-type="ref"} Therefore, RAS inhibitors such as angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker may be helpful to CAS patients since RAS is known to be closely associated with endothelial function, and RAS inhibitors are known to improve endothelial dysfunction in patients with hypertension.[12](#jah31629-bib-0012){ref-type="ref"}, [13](#jah31629-bib-0013){ref-type="ref"} However, the long‐term effects of RAS inhibitors are not studied thoroughly enough for use in CAS patients yet. Thus, we sought to evaluate the impact of RAS inhibitors on long‐term clinical outcomes in CAS patients as documented with the Ach provocation test.

Possible Mechanisms by Which RAS Inhibitors Render Favorable Effects on VSA Patients {#jah31629-sec-0017}
------------------------------------------------------------------------------------

Vascular endothelial cells express angiotensin‐converting enzyme, which mediates a conversion of angiotensin I to angiotensin II. Then, angiotensin II decomposes peptides of kinin series such as bradykinin or kallidin, which has a vasodilating effect. In the vasculature, angiotensin II causes elevation of blood pressure, vasoconstriction, proliferation or migration of smooth muscle cells, inhibition of the activation of NO via increasing reactive oxygen species, etc.[13](#jah31629-bib-0013){ref-type="ref"}, [19](#jah31629-bib-0019){ref-type="ref"} Angiotensin receptor blocker may improve endothelial function by inhibiting the action of angiotensin II by blocking angiotensin II type I receptors at the endothelium. Also, angiotensin‐converting enzyme inhibitors may improve endothelial function by interfering with the conversion of angiotensin I to angiotensin II.

Administration of these medications has been considered a mere symptomatic treatment thus far. However, the result of the present study shows that RAS inhibitor has preventive effects on total MACE and recurrent angina in VSA patients. Also, our study results provide clinical evidence that RAS inhibitor may be effective due to an association between RAS and endothelial function. Although CCBs could reduce major cardiovascular complications in VSA patients, persistent angina still remains a challenging problem.[5](#jah31629-bib-0005){ref-type="ref"}, [9](#jah31629-bib-0009){ref-type="ref"} Also, several studies reported that chronic nitrate therapy does not improve long‐term prognosis of VSA patients when combined with CCBs.[10](#jah31629-bib-0010){ref-type="ref"}, [11](#jah31629-bib-0011){ref-type="ref"} It may lead to problems in tolerance, and even raise cardiovascular risks. Seo et al reported that despite combination therapy with CCBs and nitrates, which improved chest pain, the spasmodic nature of coronary arteries still remained.[20](#jah31629-bib-0020){ref-type="ref"} In this situation, RAS blocker may provide an additional role in controlling significant CAS for improving longer‐term clinical outcomes.

Clinical Outcomes in the Entire Population, Matched Population, and Subgroup {#jah31629-sec-0018}
----------------------------------------------------------------------------

A total of 3349 CAS patients were enrolled in this study. Among these, 44.4% of patients received hypertensive medications, 19.8% received RAS inhibitors, and 84.5% received CCBs (the majority of which were diltiazem). Although the RAS inhibitor group exhibited worse clinical baseline characteristics than the non‐RAS inhibitor group, there was no difference in clinical outcomes such as total MACE and recurrent angina during the 5‐year follow‐up. However, when analyzed with PSM analysis after balancing the baseline characteristics, the RAS inhibitor group showed a lower incidence of recurrent angina (8.7% versus 14.1%, *P*=0.027), total death (0.0% versus 1.3%, *P*=0.045), and total MACE (1.0% versus 4.1%, *P*=0.026) than the non‐RAS inhibitor group (Figure [2](#jah31629-fig-0002){ref-type="fig"}). Interestingly, RAS inhibitor significantly reduced the risk of total MACE when combined with CCBs, as it did for the risk of recurrent angina when combined with nitrates (Figure [3](#jah31629-fig-0003){ref-type="fig"}).

Hypertension, diabetes mellitus, and dyslipidemia are well‐known cardiovascular risk factors, and in CAS patients with such risk factors, RAS inhibitor may help to prevent cardiovascular events from occurring. In the present study, after PSM analysis (n=1048 total), among these patients, 75.7% had a history of hypertension. During the 5‐year clinical follow‐up, the use of RAS inhibitors significantly reduced the incidence of recurrent angina and total MACE in subgroups exhibiting uncontrolled blood pressure and uncontrolled hypertension. In a previous study by Chen et al, hypertension and uncontrolled blood pressure were negatively associated with CAS.[15](#jah31629-bib-0015){ref-type="ref"} This effect may have been influenced by using RAS inhibitors for hypertension treatment. RAS inhibitors are known to potentially improve both endothelial function and insulin resistance and prevent a new onset of diabetes mellitus, as several studies have reported that RAS inhibitors improved endothelial function in patients with hypertension and type I diabetes mellitus.[12](#jah31629-bib-0012){ref-type="ref"}, [19](#jah31629-bib-0019){ref-type="ref"}, [21](#jah31629-bib-0021){ref-type="ref"}, [22](#jah31629-bib-0022){ref-type="ref"} Similarly, the present study showed that RAS inhibitors significantly reduced the incidence of total MACE during the long‐term clinical follow‐up of diabetic patients. In the series, RAS inhibitors significantly reduced the incidence of total MACE in dyslipidemia. Nickenig et al reported that hypercholesterolemic rabbits display enhanced vascular expression of angiotensin II type I receptors, which mediate an increased activity of angiotensin II.[23](#jah31629-bib-0023){ref-type="ref"} RAS inhibitor may potentially have a beneficial effect on CAS patients with dyslipidemia.[20](#jah31629-bib-0020){ref-type="ref"} In the present study, RAS inhibitors significantly reduced the incidence of recurrent angina and total MACE in female and elderly patients (≥60). Recently, Kawana et al reported that there is a sex‐specific difference in characteristics and outcomes of VSA patients.[24](#jah31629-bib-0024){ref-type="ref"} They showed that the prevalence of CAS was higher in men than women despite showing no difference in MACE during the 5‐year follow‐up, which suggests the importance of sex‐specific management in VSA patients.

In this study, there were several limitations. First, the present study was analyzed retrospectively, and PSM analysis was performed to minimize the confounding factors that might influence the results otherwise. Also, the registry was designed with an all‐comer prospective registry from 2004. However, we could not adjust for all the limiting factors not shown through medical records or collected through telephone contact. Second, the rate of (+) Ach provocation test was relatively higher due to relatively less strict diagnostic criteria, (which uses 70% narrowing cut‐off value) as compared with other criteria such as subtotal or total occlusion by Ach provocation, particularly with A1 and A2 dose and visual assessment at the time of Ach provocation test for patient\'s safety. Third, only medication information attained through diagnosis was used. Although medication history is very important for a more detailed analysis, each patient\'s drug dosage, duration of prescription, and change of drugs were too complex to analyze. However, all patients received anti‐anginal medications until free of angina symptoms and clinical remission. All the VSA patients were strongly recommended to maintain lower doses of anti‐anginal medications for safety. Also, patients received different disease‐modifying medications for hypertension, dyslipidemia, diabetes mellitus, and other risk factors according to their needs. Fourth, RAS inhibitor‐type medications were prescribed at the discretion of individual clinicians for controlling either risk factors or CAS. Therefore, there might be a potential bias, although we did use PSM to adjust for any possible bias during medication selection.

In conclusion, the use of RAS inhibitor on CAS patients was associated with improved long‐term clinical outcomes and reduced incidences of cardiovascular events in the 5‐year follow‐up. These findings suggest that the RAS inhibitor may play an important role in the long‐term clinical treatment of CAS.
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